Maia Wealth LLC Raises Stock Holdings in Abbott Laboratories $ABT

Maia Wealth LLC lifted its stake in shares of Abbott Laboratories (NYSE:ABT) by 69.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 11,542 shares of the healthcare product maker’s stock after acquiring an additional 4,711 shares during the period. Maia Wealth LLC’s holdings in Abbott Laboratories were worth $1,453,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Cloud Capital Management LLC acquired a new stake in shares of Abbott Laboratories during the 3rd quarter worth about $29,000. Guerra Advisors Inc acquired a new position in shares of Abbott Laboratories in the third quarter valued at approximately $31,000. Anfield Capital Management LLC raised its position in shares of Abbott Laboratories by 81.3% in the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after buying an additional 104 shares during the last quarter. Delos Wealth Advisors LLC purchased a new position in shares of Abbott Laboratories during the second quarter valued at approximately $32,000. Finally, Bridge Generations Wealth Management LLC acquired a new stake in Abbott Laboratories during the third quarter worth approximately $33,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Stock Down 0.1%

Shares of NYSE ABT opened at $107.99 on Friday. The stock has a market capitalization of $187.66 billion, a PE ratio of 29.03, a P/E/G ratio of 1.72 and a beta of 0.74. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. The firm has a fifty day moving average of $114.58 and a 200-day moving average of $123.91. Abbott Laboratories has a 52-week low of $105.27 and a 52-week high of $139.06.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting the consensus estimate of $1.50. The company had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The firm’s revenue was up 4.4% on a year-over-year basis. During the same period in the prior year, the firm posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $0.63 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 annualized dividend and a yield of 2.3%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 67.74%.

Insider Activity

In other Abbott Laboratories news, EVP Mary K. Moreland sold 613 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $70,850.54. Following the completion of the sale, the executive vice president directly owned 104,291 shares in the company, valued at $12,053,953.78. The trade was a 0.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $102,288.30. Following the completion of the sale, the executive vice president directly owned 146,377 shares of the company’s stock, valued at $16,918,253.66. The trade was a 0.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 3,055 shares of company stock valued at $353,097 over the last quarter. 0.46% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

ABT has been the subject of several analyst reports. Piper Sandler cut their price target on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating for the company in a report on Friday, January 23rd. The Goldman Sachs Group lowered their price objective on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a research report on Friday, January 23rd. Raymond James Financial dropped their target price on Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Freedom Capital upgraded Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 29th. Finally, Royal Bank Of Canada lowered their price target on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and a consensus target price of $136.16.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.